JaroslawPMaciejewskiMD

Hematology • Cleveland, OH

Professor of Medicine, Case West Res University

Join to view full profile

Dr. Maciejewski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Maciejewski's full profile

Already have an account?

Office
9500 Euclid Ave
Cleveland, OH 44195
Phone+1 800-223-2273

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1998 - 2000
University of Nevada Reno School of MedicineResidency, Internal Medicine, 1995 - 1998
Humboldt University of Berlin - Charite Faculty of MedicineClass of 1990

Certifications & Licensure

OH State Medical License 2001 - 2026
DC State Medical License 2000 - 2002
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
Northern Ohio Live Castle Connolly, 2008
Elected Member The American Society for Clinical Investigation, 2006
Join now to see all

Clinical Trials

Identifying Characteristics of Bone Marrow Failure Syndromes Start of enrollment: 2006 Apr 01
Unknown status
Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia Start of enrollment: 2006 May 01
Unknown status
Phase 1, Phase 2
A Phase 2 Study of R115777 in Large Granular Lymphocyte (LGL) Leukemia Start of enrollment: 2006 May 01
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome Start of enrollment: 2007 Apr 01
Unknown status
Phase 2
Join now to see all

Publications & Presentations

PubMed

3 citations
Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria.
David Dingli, Carlos De Castro Iii, Jamie Koprivnikar, Austin Kulasekararaj, Jaroslaw Maciejewski
Hematology. 2024-12-01
Clonal hematopoiesis in large granular lymphocytic leukemia.
Naomi Kawashima, Carmelo Gurnari, Carlos Bravo-Perez, Yasuo Kubota, Simona Pagliuca
Leukemia. 2024-11-21
Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis.
Damien Luque Paz, Nico Gagelmann, Lina Benajiba, Jérémie Riou, Rachel B Salit
Blood Advances. 2024-11-19

Journal Articles

Germline Loss of Function SAMD9 and SAMD9L Alterations in Adult Myelodysplastic Syndromes
Samuel Li, Mikkael A Sekeres, Jaroslaw P Maciejewski, Rabi Hanna, Blood
Mutational Landscape of myelodysplastic/myeloproliferative Neoplasm – Unclassifiable (MDS/MPN-U)
Aziz Nazha, Rami S Komrokji, Andrew Sochacki, Mikkael A Sekeres, Prithviraj Bose, Courtney D DiNardo, Hagop M Kantarjian, Srdan Verstovsek, Sanam Loghavi, Jaroslaw P M..., Blood

Abstracts/Posters

Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate PotentialClinically Relevant Abstract
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoie...
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor ExpansionClinically Relevant Abstract
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Genetics of Monosomy 7 and Del(7q) in MDS Informs Potential Therapeutic Targets
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and My...
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Reversible TET Inhibitor As a Hematopoietic Stem Cell Booster: A Novel Strategy to Improve Stem Cell Function
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Molecular Characterization of Leukemia Evolving from Paroxysmal Nocturnal Hemoglobinuri
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study ...
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/9/2019
RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Integrated Analysis of Copy-Number Alterations and Gene Mutations in 2,000 Patients with Myeloid Neoplasms
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in AdultsClinically Relevant Abstract
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Resul...
Jaroslaw P. Maciejewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Press Mentions

Beta-Thalassemia Gene Tx Gets Ringing Endorsement from FDA AdvisersJune 10th, 2022
Researchers, Including Indian-American, Identify Drugs to Treat Blood & Bone MarrowDecember 27th, 2020
Cancer Researchers Identify Potential New Class of Drugs to Treat Blood and Bone Marrow Cancers (Medicine)December 15th, 2020
Join now to see all

Grant Support

Molecular Pathogenesis Of MDS And CMMLNational Heart, Lung, And Blood Institute2010–2012
Training/Research Center-Bone Marrow Failure SyndromesNational Heart, Lung, And Blood Institute2010–2011
Viral Pathogenesis Of Idiopathic Bone Marrow Failure And Immune CytopeniasNational Institute Of Allergy And Infectious Diseases2009–2011
Translational Hematology And Oncology Research Laboratory Expansion ProjectNational Center For Research Resources2010
Training/Research Center--Bone Marrow Failure SyndromesNational Heart, Lung, And Blood Institute2005–2009
TCR Diagnostics In LGL Leukemia And Immune CytopeniasNational Cancer Institute2005–2009
Predisposition To Chromosomal Alterations In MDSNational Heart, Lung, And Blood Institute2005–2008
Bone Marrow Failure Clinical Research CenterNational Center For Research Resources2004–2008
Molecular T Cell Repertoire In Aplastic AnemiaNational Heart, Lung, And Blood Institute2004–2007
Bone Marrow Failure Scientific SymposiumNational Heart, Lung, And Blood Institute2004
Bone Marrow Failure Clinical Research CenterNational Center For Research Resources2003